Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Systemic scleroderma is an autoimmune disease that affects the skin as well as the internal organs such as lungs, muscles, blood vessels, digestive system, or kidneys. When the immune system malfunctions and attacks the body's own tissues and organs, autoimmune disorders occur. Scleroderma is a group of rare diseases that causes the skin and connective tissues to harden and tighten.
Systemic scleroderma is also known as systemic sclerosis as the fibrosis can affect organs other than the skin. Fibrosis is caused by an increase in the production of collagen, a tough protein that normally strengthens and supports connective tissues throughout the body.
There is no medication that can cure or stop the excessive collagen production that is characteristic of scleroderma. A number of medications, however, can help control scleroderma symptoms and prevent complications.
The treatment is dependent on the symptom, which include corticosteroids, immunosuppressant such as methotrexate, medication to aid breathing, light therapy such as ultraviolet A1 phototherapy, and blood pressure medications.
Global Systemic Scleroderma Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 213 million cases and 4.48 million deaths due to coronavirus disease (COVID-19) were reported till August 25, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Systemic Scleroderma Treatment
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Patients with autoimmune disorders may be more vulnerable to COVID-19. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global systemic scleroderma treatment market during the forecast period. For instance, according to the article published in the journal ‘Clinical Rheumatology’ in November 2020, a significantly higher prevalence of COVID-19 is observed in a large number of patients with autoimmune systemic diseases in the hospital in Italy compared to the Italian general population, owing to patients' increased susceptibility to COVID-19 infections and aided by high exposure to the virus at medical facilities prior to individual movement restrictions.
The global systemic scleroderma treatment market is estimated to be valued at US$ 1.51 Bn in 2021, and is expected to exhibit a CAGR of 4.0 % over the forecast period (2021-2028).
Figure 1: Global Systemic Scleroderma Treatment Market Share (%) Analysis, By Drug Class, 2021
The increase in cases of autoimmune diseases is the major factor that is expected to drive the growth of global systemic scleroderma treatment market over the forecast period.
The emerging prevalence of autoimmune diseases is expected to drive the growth of the global systemic scleroderma treatment market. For instance, according to the International Autoimmune Institute & Bingham Memorial Center for Functional Medicine, in 2017, 50 million Americans, 80 percent of whom were women, were diagnosed with one or more autoimmune diseases in the U.S. An autoimmune disease affects one in every twelve Americans, or one out of every nine women in the U.S.
Systemic Scleroderma Treatment Market Report Coverage
||Market Size in 2021:
||US$ 1.51 Bn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1.99 Bn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Class: Immunosuppressant, Phosphodiesterase 5 Inhibitors (PHA), Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.
- Increasing cases of autoimmune diseases
- Increasing product launches and approvals
- Increasing research and development activities by the market players
Research and Development Activities
Increasing number of research and development activities is expected to aid in the growth of the global systemic scleroderma treatment market over the forecast period. For instance, in June 2021, Horizon Therapeutics plc., a company dedicated to researching, developing, and commercializing medicines to meet the critical needs of people affected by rare and rheumatic diseases, launched a phase 2 multicenter trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis, which is still ongoing. HZN-825 is an oral therapy that is intended to prevent the onset of skin fibrosis (scarring) by blocking the lysophosphatidic acid 1 receptor protein (LPAR1) for treatment of systemic sclerosis. The result of the first phase showed that eight weeks of treatment with HZN-825 reduced skin thickness slightly, with a greater effect in normalizing changed expression of lysophosphatidic acid (LPA)-associated genes than a placebo.
Global Systemic Scleroderma Treatment Market – Regional Analysis
On the basis of region, the global systemic scleroderma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global systemic scleroderma treatment market over the forecast period, owing to the new product launches and approvals. For instance, on September 9, 2019, Boehringer Ingelheim, one of the world's largest pharmaceutical companies, announced that the U.S. Food and Drug Administration (FDA) had approved Ofev (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev is also designated as an Orphan Drug, which provides incentives to assist and encourage the development of drugs for rare diseases.
Moreover, due to strategic collaborations between market players and academic institutes, Europe is expected to witness a significant growth in the global systemic scleroderma treatment market over the forecast period. For instance, on December 10, 2019, Servier Laboratories, a private international pharmaceutical company based in France, partnered with the University Of College London (UCL) in a two-year agreement in which Servier would share scientific knowledge and support with two UCL-led research projects. These studies aim to investigate that which pathways are pathologically altered in lupus patients and how systemic sclerosis develops. The teams hope to develop much-needed new drugs and therapeutic approaches to treat the conditions by better understanding the mechanisms underlying each disease.
Figure 2: Global Systemic Scleroderma Treatment Market Value (US$ Bn), by Region, 2021
Global Systemic Scleroderma Treatment Market – Competitive Landscape
Major players operating in the global systemic scleroderma treatment market include Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc., Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.